In patients with CSCC that had spread or could not be cured by surgery or radiation LIBTAYO helped tumors shrink or completely disappear in some clinical trial patients

LIBTAYO was studied in 2 clinical trials

LIBTAYO has been studied in 219 patients in 2 clinical trials of patients with CSCC that had spread or could not be cured by surgery or radiation.

In 1 clinical trial of 137 patients with CSCC that had spread or could not be cured by surgery or radiation treated with LIBTAYO*:

46% of patients
(63 out of 137) saw an improvement in their condition with LIBTAYO (objective response rate)

Complete response15% of patients (20 out of 137)
saw tumors disappear completely
Partial response31% of patients (43 out of 137)
saw tumors shrink
In patients who responded to LIBTAYO, responses lasted 6 months or longer in 50 out of 63 patients (79%) and 12 months or longer in 34 out of 63 patients (54%).

In the same clinical trial, in a separate group of 56 patients with CSCC that had spread who took LIBTAYO at the recommended dose:

  • 23 out of 56 patients (41%) saw an improvement in their advanced CSCC with LIBTAYO
    • 20 out of 56 patients (36%) saw tumors shrink (partial response)
    • 3 out of 56 patients (5%) saw tumors disappear completely (complete response)
  • In 15 out of 23 patients (65%) who responded to LIBTAYO, the response lasted 6 months or longer

In a different clinical trial of 26 patients with CSCC that had spread or could not be cured by surgery or radiation*:

  • 13 out of 26 patients (50%) saw tumors shrink (all partial responses)
    • In 11 out of 13 patients (85%) who responded to LIBTAYO, the response lasted 6 months or longer

In these trials, responses lasted between 1 month and more than 2 years (24.2+ months); plus sign (+) denotes ongoing at last assessment.


*Patients were dosed by body weight.

LIBTAYO 350 mg over a 30-minute infusion every 3 weeks.

Patient examples